Read
- French soldier stabbed while on patrol near Paris
- REPEAT-Will immigration reform get killed in Republican-led U.S. House?
- Planetary alignment peaks with celestial show this weekend
- Rockets hit south Beirut after Hezbollah vows Syria victory
- Two believed dead as heavy rains flood San Antonio streets
|
Sponsored Links
SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations...
* Reuters is not responsible for the content in this press release.
SIGA Technologies, Inc. Retains KCSA Strategic Communications as Investor Relations Counsel NEW YORK--(Business Wire)-- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced it has retained KCSA Strategic Communications to implement a comprehensive investor relations program. Commenting on the appointment, Eric A. Rose, MD, Chief Executive Officer, said, "This is an exciting time for our Company. We have built an impressive biological warfare defense product portfolio and we look forward to working with KCSA to raise awareness of these agents while communicating our strategy for success to the investment community. We believe KCSA has the resources in place to help convey our unique position in the Biotech and Pharmaceuticals sectors and to support our communications efforts with Wall Street." Todd Fromer, managing partner of KCSA Strategic Communications, added, "We are excited to have been selected as SIGA Technologies' communications partner. The Company presents a compelling story and management has expressed a strong commitment to increase awareness among core constituents. We look forward to providing our integrated services and the full range of our expertise in support of SIGA's communications initiatives." About SIGA Technologies, Inc. SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential biowarfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's Web site at http://www.siga.com/. About KCSA Strategic Communications Now in its 39th year, KCSA Strategic Communications (www.kcsa.com) is an integrated communications agency that helps clients synchronize their brand messages across investor relations, public relations and all other strategic marketing channels. The firm offers its clients a rare opportunity to achieve true brand alignment and develop close, meaningful relationships with their key audiences. KCSA is a founding member of ECP Global (www.ecpglobal.com), an international alliance of premier independent communication consultancies. KCSA Strategic Communications Todd Fromer, 212-896-1215 Tfromer@kcsa.com Marybeth Csaby, 212-896-1236 mcsaby@kcsa.com David Burke, 212-896-1258 dburke@kcsa.com Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.


Follow Reuters